CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
BioRegenx›
Library
BioRegenx logo

BioRegenx

US-based Bioregenx LLC. manufactures and sells healthcare and surgical supplies.

Chattanooga, TN, US🇺🇸
Founded
2021
Loading
Overview
Compare
Fundraising
Employees
Library

BioRegenx - Library

bioregenx.com·Crawled Oct 16, 2026·

Topics

Publication type

Content origin
Row density

Blog

1 page
  1. Blog/blog

Press

6 pages
  1. BioRegenx Announces microvascular dysfunction in sepsis study using the medical testing device GlycoCheck/press/bioregenx-announces-microvascular-dysfunction-in-sepsis-study-using-the-medical-testing-device-glycocheck

    BioRegenx, Inc. and its subsidiary Microvascular Health Solutions announced a peer-reviewed GlycoCheck study on microvascular dysfunction in sepsis, published in Critical Care.

  2. BioRegenx Announces Study Using GlycoCheck that Links Psoriasis with Endothelial Glycocalyx Health/press/bioregenx-announces-study-using-glycocheck-that-links-psoriasis-with-endothelial-glycocalyx-health

    BioRegenx, Inc. and its subsidiary Microvascular Health Solutions announced a peer-reviewed GlycoCheck study on endothelial glycocalyx and microvascular perfusion in psoriatic disease, using an FDA-registered Class 1 medical testing device.

  3. Microvascular Health Solutions Announces Cellular Reconditioning for Kidney Regeneration using GlycoCheck/press/microvascular-health-solutions-announces-cellular-reconditioning-for-kidney-regeneration-using-glycocheck

    Microvascular Health Solutions announced a peer-reviewed study titled “Ways and Means of Cellular Reconditioning for Kidney Regeneration,” which also examined its Endocalyx Pro nutraceutical. The study was published in the American Journal of Nephrology.

  4. Microvascular Health Solutions Announces High-Intensity Interval Exercise Study Using Its’ Testing Device GlycoCheck/press/microvascular-health-solutions-announces-high-intensity-interval-exercise-study-using-its-testing-device-glycocheck

    Microvascular Health Solutions announced a peer-reviewed study titled “Effects of high-intensity interval training on microvascular glycocalyx and associated microRNAs.” The study examined how high-intensity interval training affects the microvasculature, including the endothelial glycocalyx.

Team

1 page
  1. Team/team

    The company’s directors and staff include professionals with experience at Goldman Sachs, Dow Chemical, Sony, CitiFinancial and other Fortune 500 companies, as well as members with PhDs and medical degrees.

Contact

1 page
  1. Contact Us/contact-us

    The page provides a form for email updates.

Homepage

1 page
  1. Homepage/

    BioRegenx, Inc. leads the way in the science of the endothelial glycocalyx with patented imaging technology, the GlycoCheck system and the patented formula for regeneration of the glycocalyx and microvascular system.